Shoham, S., Bloch, E. M., Casadevall, A., Hanley, D., Lau, B., Gebo, K., Cachay, E., Kassaye, S. G., Paxton, J. H., Gerber, J., Levine, A. C., Naeim, A., Currier, J., Patel, B., Allen, E. S., Anjan, S., Appel, L., Baksh, S., Blair, P. W., Bowen, A., Broderick, P., Caputo, C. A., Cluzet, V., Cordisco, M. E., Cruser, D., Ehrhardt, S., Forthal, D., Fukuta, Y., Gawad, A. L., Gniadek, T., Hammel, J., Huaman, M. A., Jabs, D. A., Jedlicka, A., Karlen, N., Klein, S., Laeyendecker, O., Lane, K., McBee, N., Meisenberg, B., Merlo, C., Mosnaim, G., Park, H., Pekosz, A., Petrini, J., Rausch, W., Shade, D. M., Shapiro, J. R., Singleton, J. R., Sutcliffe, C., Thomas, D. L., Yarava, A., Zand, M., Zenilman, J. M., Tobian, A. A. R., & Sullivan, D. J. (2023). transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clinical infectious diseases, 76, e477–e486. http://access.bl.uk/ark:/81055/vdc_100177581951.0x000018